Clinical toxicology of newer recreational drugs
Clinical Toxicology October 1, 2011 DOI: 10.3109/15563650.2011.615318 via OpenAlex
Summary
AI-generated from the abstractClinicians have limited reliable data to guide management of patients with toxicity from emerging recreational drugs. The harms of these substances are not fully documented, though they are clearly not without risk. Current acute management is pragmatic, primarily extrapolated from experience with longer-established stimulant or hallucinogenic drugs such as amphetamines, MDMA, and LSD.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Clinical toxicology Recreational drug Pharmacology Intensive care medicine |
| Citations | 289 |
| Key finding | Management of acute toxicity from emerging recreational drugs is pragmatic and largely extrapolated from experience with established stimulant or hallucinogenic drugs. |
Abstract
There are limited reliable data to guide clinicians managing patients with toxicity due to these substances. The harms associated with emerging recreational drugs are not fully documented, although it is clear that they are not without risk. Management of users with acute toxic effects is pragmatic and primarily extrapolated from experience with longer established stimulant or hallucinogenic drugs such as amfetamines, 3,4-methylenedioxymethamfetamine (MDMA) and lysergic acid diethylamide (LSD).